1. Abel ED, Houseknecht KL, Kahn BB. Recent advances in understanding the molecular basis for insulin stimulated glucose transport. Current Opinion in Endocrinology and Diabetes 1995,2(4):313-324.

  2. Abel ED, Shepherd PR, Kahn BB. Glucose transporters and pathophysiologic states. In Diabetes Mellitus a Fundamental and Clinical Text. Edited by Leroith D, Olefsky JM and Taylor S. Philadelphia: JB Lipincott; 1996: 530-543.

  3. McCowen KC, Abel ED, The contribution of defects in insulin signaling in skeletal muscle to insulin resistance and Type 2 diabetes: cellular and molecular aspects. In Advances in Structural Biology. Malhotria S. Editor. JAI Press. Volume 6:2000:41-64.

  4. Shepherd PR, Abel ED, Kahn BB. Glucose transporters and pathophysiologic states. In Diabetes Mellitus a Fundamental and Clinical Text (Second Edition). Edited by Leroith D, Olefsky JM and Taylor S. Philadelphia. JB Lipincott; 2000:627-641.

  5. Abel ED, Glucose transporters and cardiac function. Insights from heart selective GLUT4 knockout mice. In, Frontiers in animal diabetes research. Volume 3. Insulin signaling: From cultured cells to animal models. Eds. G. Grunberger and Y. Zick. 2002:397-408.

  6. Abel ED, Shepherd PR, Kahn BB. Glucose transporters and pathophysiologic states. In Diabetes Mellitus a Fundamental and Clinical Text. Edited by Leroith D, Olefsky JM and Taylor S. Philadelphia: JB Lipincott; 2003: 917-938.

  7. Vidal-Puig AJ, Abel ED, Insulin resistance and cardiovascular disease-New insights from genetics. In Handbook of Experimental Pharmacology –Volume: Cardiovascular Pharmacogenetics. Edited by Martin R. Wilkins. Heidelberg. Springer-Verlag. 2004: 243-279.

  8. Abel ED, Glucose transport in the heart. Frontiers in Bioscience. 2004; 9: 201-215. PMID: 14766360

  9. Abel ED, Insulin signaling in cardiac muscle: Lessons from genetically engineered mouse models. Curr. Reports in Hypertension. 2004; 6: 416-423. PMID: 15527684

  10. Abel ED, Myocardial insulin resistance and cardiac complications of diabetes. Curr. Drug Targets –Immune, Endocrine and Metabolic Disorders. 2005: 5; 219-226. PMID: 16089356

  11. Abel ED, Metabolic perturbations in the diabetic heart: Mechanisms and molecular targets. Drug Discovery Today: Disease Mechanisms. 2005: 2; 115-122.

  12. O’Neill BT, Abel ED, Akt1 in the cardiovascular system: friend or foe? Journal of Clinical Investigation. 2005:115; 2059-2064. PMID: 16075047, PMC: 1180557

  13. Boudina S, Abel ED, Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. Physiology. 2006:21; 250-258. PMID: 16868314
  14. Hsueh WA, Abel ED, Breslow JL, Maeda N, Davis RC, Fisher EA, Dansky H, McClain DA, McIndoe R, Wassef MK, Rabadan-Diehl C, Goldberg IJ. Recipes for creating animal models of diabetic cardiovascular disease. Circulation Research. 2007:100; 1415-1427. PMID: 17525381

  15. Boudina S, Abel ED, Diabetic cardiomyopathy revisited. Circulation. 2007:115; 3213-3223. PMID: 17592090

  16. Abel ED, Glucose for the aging heart? Circulation. 2007: 116:884-887. PMID: 17709649

  17. Bugger H, Abel ED, Molecular mechanisms of myocardial mitochondrial dysfunction in the metabolic syndrome. Clinical Science. 2008: 114(3):195-210. PMID: 18184113

  18. Abel ED, Litwin SE, Sweeney GD. Cardiac remodeling in obesity. Physiological Reviews. 2008: 88:389-419. PMID: 18391168, PMC: 2915933

  19. Bugger H, Abel ED, Molecular basis of cardiac efficiency. Heart and Metabolism. 2008: 39:1-5.

  20. Bugger H. Abel ED, Rodent models of diabetic cardiomyopathy. Disease Models and Mechanisms. 2009: 2, 454-466. PMID: 19726805

  21. Wende AR, Abel ED, Lipotoxicity in the heart. Biochim Biophys Acta.2010: 1801: 311–319. PMID: 19818871, PMC: 2823976

  22. Boudina S, Abel ED, Diabetic cardiomyopathy, causes and effects. Rev Endocr Metabo Disord. 2010. 11:31-9. PMID: 20180026, PMC: 2914514

  23. Sweeney GD, Litwin SE, Abel ED, Obesity and cardiac dysfunction. In Metabolic Basis of Obesity. Edited by Rexford A. Ahima. New York. Springer-Verlag. 2010: In press.

  24. Bugger H, Abel ED, Mitochondria in the diabetic heart. Cardiovascular Research. 2010 88(2): 229-40. PMID: 20639213, PMC: 2952534

  25. Abel ED, Free fatty acid oxidation in insulin resistance and obesity. Heart and Metabolism. 2010: 48:1-6.

  26. Abel ED, Obesity Stresses Cardiac Mitochondria Even When you are Young J. Amer Coll Cardiol. 2011: 57:586-9.

  27. Abel ED, Doenst T. Mitochondrial adaptations to physiological versus pathological cardiac hypertrophy. Cardiovascular Research. 2011: 90(2): 234-42. PMID: 21257612, PMC: 3115280

  28. Abel ED, A new twist in the function of the cardiac lipid droplet. Nature Medicine: 2011: 17:1045-6.

  29. Targeting myocardial substrate metabolism in heart failure: Potential for new therapies. Ardehali H, Sabbah HN, Burke MA, Sarma S, Liu PP, Cleland JGF, Maggioni A, Gregg C. Fonarow GC, Abel ED, Campia U, Gheorghiade M..Eur J Heart Failure. 2012. 14:120-9.

  30. Bugger H, Abel ED, Endonuclease G: the link between mitochondria and cardiac hypertrophy? Circulation Research. 2012. 110:378-80.

  31. Abel ED, Sweeny G. Modulation of the cardiovascular system by leptin. Biochimie. 2012; 94:2097-103. PMID:22490727

  32.  Abel ED, O'Shea K, Ramasamy R. Insulin resistance: metabolic mechanisms and consequences in the heart, Arteriosclerosis, Thrombosis, and Vascular Biology. 2012; 32(9): 2068-76. PMID: 22895668, PMC: 3646067

  33. Wende AR, Symons JD, Abel ED. Mechanisms of lipotoxicity in the cardiovascular system. Current Hypertension Research. 2012; 14(6): 517-31. PMID: 23054891, PMC: 3491122

  34. Riehle C, Abel ED. PGC-1 proteins and heart failure, Trends in Cardiovascular Medicine. 2012; 22(4): 98-105. PMID: 22939990, PMC: 3466400

  35. Ardehali H, Sabbah H, Burke M, Sarma S, Liu P, Cleland J, Maggioni A, Gregg C, Fonarow G, Abel ED, Campia U, Gheorghiade M. Targeting myocardial substrate metabolism in heart failure: potential new therapies, European Journal of Heart Failure. 2012; 14: 120-9. PMID: 22253453, PMC: 3260022

  36. Gottlieb RA, Quarato GV, Abel ED.  Mitochondria in cardiac disease.  In Molecular and Translational Medicine.  Edited by Cam Patterson and Monte Willis.  New York.  Springer-Science + Business Media.  2012.  In Press.

  37. Doenst T, Nguyen T, Abel ED, Cardiac Metabolism in Heart Failure-Implications Beyond ATP Production, Circulation Research. 2013; 113: 709-724. PMID: 23989714, PMC: 3896379

  38. Symons JD, Abel ED. Lipotoxicity contributes to endothelial dysfunction: a focus on the contribution from ceramide. Reviews in Endocrine & Metabolic Disorders. 2013; 4(1): 59-68. PMID: 23292334

  39. Graham TE, Abel ED.  Autophagy in Diabetes and the Metabolic Syndrome.  In Autophagy in Health and Disease.  Edited by Roberta Gottlieb, London, New York, San Diego.  Academic Press – Elsevier. 2013;117-139.

  40. Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy, Diabetologia. 2014. In Press. PMID: 24477973

  41. Nair KS, Abel ED, Adler SG, Dyck PJ, Gardner TW, Haskins KM, Hotamisligil G, Jensen MD, Krook A, Mandarino LJ, Mitchell BD, Pessin JE, Sowers JR, Sussel L, Wareham N, Vella A.  Time to look back and time to look forward. Diabetes. 2014 Apr;63(4):1169-70.
     
  42. Taegtmeyer H, Young ME, Lopaschuk GD, Abel ED, Brunengraber H, Darley-Usmar V, Des Rosiers C, Gerszten R, Glatz JF, Griffin JL, Gropler RJ, Holzhuetter HG, Kizer JR, Lewandowski ED, Malloy CR, Neubauer S, Peterson LR, Portman MA, Recchia FA, Van Eyk JE, Wang TJ. Assessing Cardiac Metabolism: A Scientific Statement From the American Heart Association., Circulation research. 2016 March 24. PMID:27012580. doi: 10.1161/RES.0000000000000097.
     
  43. Riehle C, Abel ED. Insulin Signaling and Heart Failure., Circulation research. 2016 April 1;118(7):1151-69. PMID:27034277. doi: 10.1161/CIRCRESAHA.116.306206.
     
  44. Jaishy B, Abel ED. Lipids, Lysosomes and Autophagy., Journal of lipid research. 2016 June 21. PMID:27330054. doi: 10.1194/jlr.R067520.